We are live on ! Find out more
RI

RTW Investments Portfolio holdings

AUM $10B
1-Year Est. Return 135.35%
This Fund
S&P 500
This Quarter Est. Return
+18.13%
1 Year Est. Return
+135.35%
3 Year Est. Return
+383.62%
5 Year Est. Return
+523.94%
10 Year Est. Return
+15,981.64%
AUM
$4.9B
AUM Growth
+$561M
Cap. Flow
+$279M
Cap. Flow %
5.7%
Top 10 Hldgs %
55.22%
Holding
87
New
1
Increased
20
Reduced
10
Closed
10

Top Buys

Rank Stock Value
1
MRTX
Mirati Therapeutics, Inc. Common Stock
MRTX
+$114M
2
AXSM icon
Axsome Therapeutics
AXSM
+$65.6M
3
RARE icon
Ultragenyx Pharmaceutical
RARE
+$63.2M
4
IMCR icon
Immunocore
IMCR
+$62.4M
5
RCKT icon
Rocket Pharmaceuticals
RCKT
+$34.7M

Top Sells

Rank Stock Value
1
ISEE
IVERIC bio, Inc. Common Stock
ISEE
+$59.8M
2
TSVT
2seventy bio
TSVT
+$17.9M
3
TNDM icon
Tandem Diabetes Care
TNDM
+$15.4M
4
GH icon
Guardant Health
GH
+$13.5M
5
RCOR
Renovacor, Inc.
RCOR
+$7.56M

Sector Composition

Rank Sector Weight
1 Healthcare 99.63%
2 Financials 0.27%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
ALNY icon
1
Alnylam Pharmaceuticals
ALNY
$36.5B
$400M 8.17%
1,683,362
– –
RXDX
2
DELISTED
Prometheus Biosciences, Inc. Common Stock
RXDX
$369M 7.53%
3,354,303
+164,698
+5% +$10.7M
RCKT icon
3
Rocket Pharmaceuticals
RCKT
$377M
$346M 7.07%
17,687,772
+1,884,970
+12% +$34.7M
IMCR icon
4
Immunocore
IMCR
$1.74B
$317M 6.48%
5,559,322
+1,107,839
+25% +$62.4M
TMO icon
5
Thermo Fisher Scientific
TMO
$196B
$240M 4.9%
435,500
– –
AXSM icon
6
Axsome Therapeutics
AXSM
$11.7B
$230M 4.69%
2,980,482
+1,098,318
+58% +$65.6M
MASI
7
DELISTED
Masimo
MASI
$222M 4.53%
1,501,493
+61,500
+4% +$8.46M
PTCT icon
8
PTC Therapeutics
PTCT
$6.48B
$214M 4.38%
5,615,387
-5,193
-0.1% -$216K
RARE icon
9
Ultragenyx Pharmaceutical
RARE
$2.86B
$184M 3.75%
3,966,915
+1,606,919
+68% +$63.2M
ARGX icon
10
argenx
ARGX
$53.5B
$183M 3.73%
482,195
+15,000
+3% +$5.61M
MRTX
11
DELISTED
Mirati Therapeutics, Inc. Common Stock
MRTX
$165M 3.37%
3,643,114
+1,760,451
+94% +$114M
ESTA icon
12
Establishment Labs
ESTA
$2.75B
$156M 3.18%
2,374,138
+5,000
+0.2% +$302K
PEN icon
13
Penumbra
PEN
$12.5B
$155M 3.17%
698,371
– –
CLDX icon
14
Celldex Therapeutics
CLDX
$2.79B
$137M 2.81%
3,084,215
– –
RNAM
15
DELISTED
Avidity Biosciences
RNAM
$124M 2.54%
5,605,566
+434,782
+8% +$6.48M
CYTK icon
16
Cytokinetics
CYTK
$10.9B
$118M 2.41%
2,574,198
– –
ILMN icon
17
Illumina
ILMN
$28B
$114M 2.33%
580,178
– –
NTRA icon
18
Natera
NTRA
$38B
$105M 2.14%
2,609,283
+400,000
+18% +$16.5M
VCEL icon
19
Vericel Corp
VCEL
$2.36B
$81.7M 1.67%
3,099,904
– –
CUTR
20
DELISTED
Cutera, Inc.
CUTR
$79.5M 1.62%
1,798,675
+28,275
+2% +$1.29M
ACAD icon
21
Acadia Pharmaceuticals
ACAD
$4.32B
$58.4M 1.19%
3,670,938
– –
GMED icon
22
Globus Medical
GMED
$10.4B
$55.5M 1.13%
747,685
– –
AXNX
23
DELISTED
Axonics, Inc. Common Stock
AXNX
$55.3M 1.13%
884,974
– –
VTYX
24
DELISTED
Ventyx Biosciences
VTYX
$50.9M 1.04%
1,551,778
– –
RGNX icon
25
Regenxbio
RGNX
$575M
$41.9M 0.85%
1,845,366
– –
1
2 3 4

Similar funds

BEI
Benjamin Edwards Inc Clayton, Missouri $10.1B AUM 14.03% 1-Year Est. Return
MG
Mather Group Chicago, Illinois $10B AUM 15.14% 1-Year Est. Return
LWCFA
Loring Wolcott & Coolidge Fiduciary Advisors Boston, Massachusetts $9.98B AUM 4.97% 1-Year Est. Return
HRCM
Hood River Capital Management Palm Beach Gardens, Florida $9.98B AUM 145.42% 1-Year Est. Return
RA
Royce & Associates New York $10.1B AUM 42.88% 1-Year Est. Return
OAM
OP Asset Management Helsinki $9.95B AUM 30.22% 1-Year Est. Return
GI
GAMCO Investors Greenwich, Connecticut $10.2B AUM 30.27% 1-Year Est. Return
IIM
INTECH Investment Management West Palm Beach, Florida $10.2B AUM 28.14% 1-Year Est. Return

RTW Investments's Q4 2022 Portfolio in Review

As of Q4 2022, RTW Investments held 87 positions worth $4.9B, up 13% from $4.34B the previous quarter. Its ten largest holdings account for 55% of the portfolio.

RTW Investments deployed $279M of net new capital in Q4 2022, opening 1 new position and adding to 20 existing holdings. Its largest new stake was Terns Pharmaceuticals: 1,000,000 shares worth $10.2M.

By sector, the portfolio is most concentrated in Healthcare at 100% of assets, up from 99% a quarter earlier, followed by Financials.

On the sell side, the largest reduction was IVERIC bio, Inc. Common Stock, an estimated $59.8M trimmed.

  • RTW Investments's largest Q4 2022 buy was Terns Pharmaceuticals: 1,000,000 shares worth $10.2M.
  • RTW Investments added most to Mirati Therapeutics, Inc. Common Stock in Q4 2022, an estimated $114M increase.
  • RTW Investments's biggest Q4 2022 reduction was IVERIC bio, Inc. Common Stock, cutting an estimated $59.8M.
  • RTW Investments fully exited 2seventy bio in Q4 2022, selling an estimated $17.9M.
  • RTW Investments's ten largest holdings make up 55% of its $4.9B portfolio in Q4 2022.
  • RTW Investments opened 1 new position and closed 10 in Q4 2022.
  • RTW Investments's portfolio value rose 13% quarter-over-quarter to $4.9B.

Based on RTW Investments's 13F filing for Q4 2022, filed 14 Feb 2023.